A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over

Tetanus Clinical Trial

Official title:

A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06120751
• Other study ID #: CTP-TTVA-001-III
• Status: Recruiting
• Phase: Phase 3
• Start date: March 20, 2024
• Est. completion date: July 2024

Study information

• Verified date: October 2023
• Source: CanSino Biologics Inc.
• Contact: Shunda Zhang
• Phone: 022-58213600-6051
• Email: shunda.zhang[@]cansinotech.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, observer-blind, positive-controlled study. There will be 2 treatment groups, Subjects who gave informed consent and passed the questioning screen were randomly assigned 1:1 to be immunized with 1 dose of Tetanus Vaccine, Adsorbed (TTVA) or control vaccine.

Description:

Tetanus can be prevented with tetanus toxoid-containing vaccines (TT-containing vaccines, TTCVs), which are included globally in routine immunization programs for children, and in many countries at the time of prenatal care. China eliminated neonatal tetanus in 2012, but non-neonatal tetanus remains a serious public health problem. TT vaccine was first produced in 1924 and is used as a single antigen vaccine and combination vaccine component to prevent other vaccine-preventable diseases, including diphtheria, pertussis, poliomyelitis, hepatitis B, Haemophilus influenzae type b (Hib), and other vaccine-preventable diseases. Haemophilus influenzae type b (Hib).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: July 2024
• Est. primary completion date: July 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years of age and older, able to provide valid proof of identity for himself/herself.

• Ability to understand the requirements and process of the study and to agree to participate in the clinical trial and to sign an informed consent form.

• Ability to comply with the requirements of the clinical trial protocol and complete all follow-up studies.

Exclusion Criteria:

• Previously diagnosed tetanus infection.

• Vaccination against tetanus or vaccines containing tetanus toxoid antigen components (e.g., DPT, DPT, RCV, etc.) within 5 years.

• Axillary temperature >37.0°C on the day of enrollment.

• Women with a positive urine pregnancy test or during pregnancy or breastfeeding.

• Women of childbearing age, male volunteers and male volunteers whose partner is a woman of childbearing age have a pregnancy plan or birth plan during the study period.

• Persons suffering from thrombocytopenia, any coagulation disorder, or receiving anticoagulant therapy that may contraindicate intramuscular injection.

• Suffering from serious respiratory diseases, serious cardiovascular diseases, liver and kidney diseases, malignant tumors, serious infectious or allergic skin diseases, hypertension that cannot be controlled by medication (at the time of on-site measurement: systolic blood pressure =160mmHg, diastolic blood pressure =100mmHg), and being in the period of acute disease or chronic disease activity within 7 days.

• History of severe neurological disorders such as epilepsy, convulsions, encephalopathy, or history of psychiatric disorders.

• Previous history of severe allergy to vaccination or medication (anaphylaxis, anaphylactic laryngeal edema, anaphylactic purpura, thrombocytopenic purpura, localized anaphylactic necrotic reaction (Arthus reaction), etc.).

• Allergy to certain components of the vaccine used in this clinical trial (mainly tetanus toxoid, aluminum hydroxide, sodium chloride, etc.) or allergy to the above components from previous vaccination.

• Known or suspected immunological abnormalities (e.g., HIV infection, history of thyroid, pancreas, liver, spleen, kidney disease or resection), immunosuppressive therapy, cytotoxic therapy, systemic glucocorticosteroid medication (=14 days) within 6 months prior to enrollment (excluding spray corticosteroid therapy for allergic rhinitis, surface corticosteroid therapy for acute uncomplicated dermatitis, etc.) topical medications).

• Received blood products (whole blood, component blood, immune globulin, etc.) in the previous 3 months or plan to use such products within 1 month of vaccination.

• Vaccination with live attenuated vaccine within 14 days, subunit vaccine or inactivated vaccine within 7 days.

• Plans to participate or is participating in clinical studies of any other drug.

• Any circumstances that, in the judgment of the researcher, are likely to influence the assessment.

Related Conditions & MeSH terms

• Tetanus

Intervention

Biological:
• TTVA
Intramuscular injection, 1 dose of 0.5ml inoculated on Day 0
• TT
Intramuscular injection, 1 dose of 0.5ml inoculated on Day 0

Locations

Country	Name	City	State
China	Center for Disease Control and Prevention, Qixingguan District, Bijie City	Bijie	Guizhou

Sponsors (1)

Lead Sponsor	Collaborator
CanSino Biologics Inc.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Positive serum conversions of anti-tetanus toxoid IgG antibodies.		30 days after immunization
Primary	Incidence of adverse reactions (AR).		0-30 days after immunization
Secondary	Geometric mean multiplicity of increase (GMI) of anti-tetanus toxoid IgG antibodies in serum.		30 days after immunization
Secondary	Positivity rate of anti-tetanus toxoid IgG antibodies in serum.		30 days after immunization
Secondary	Geometric mean concentration (GMC) of anti-tetanus toxoid IgG antibodies in serum.		30 days after immunization
Secondary	Proportion of serum with anti-tetanus toxoid IgG antibody concentration =1.0 IU/ml		30 days after immunization
Secondary	Incidence of AR.		30 minutes after immunization
Secondary	Incidence of adverse events (AE).		0-30 days after immunization
Secondary	Incidence of AE/AR.		0-7 days post-immunization
Secondary	Incidence of serious adverse events (SAEs).		6 months post-immunization